Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans

Journal of Clinical Pharmacology

Volumn 52, Issue 9, 2012, Pages 1410-1419

  Atiee, George ^a   Lasseter, Kenneth ^b   Baughman, Sharon ^c   McCullough, Amy ^d   Collis, Phil ^d   Hollister, Alan ^d   Hernandez, Jaime ^d  

^a Icon Development Solutions   (United States)

^b Clinical Pharmacology of Miami   (United States)

^c ProPharma Services   (United States)

^d BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

Clinical trials (CTR); drug interactions; infectious diseases (INF); influenza; pharmacokinetics and drug metabolism (PDM)

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ACETYLSALICYLIC ACID; ORAL CONTRACEPTIVE AGENT; OSELTAMIVIR; PARACETAMOL; PERAMIVIR; RIMANTADINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; FEMALE; GEOMETRY; HUMAN; INFLUENZA LIKE ILLNESS; LIPOMA; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPEN STUDY; PAIN; PHARMACOLOGICAL PARAMETERS; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION; VIRAL GASTROENTERITIS; XEROSTOMIA;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CROSS-OVER STUDIES; CYCLOPENTANES; DRUG INTERACTIONS; FEMALE; GUANIDINES; HUMANS; MALE; MIDDLE AGED; OSELTAMIVIR; RIMANTADINE; YOUNG ADULT;

EID: 84866005095     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011414574     Document Type: Article

References (26)

1. Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem. 2000 ; 43: 3482-3486
2. Von Itzstein M, Wu W-Y, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature. 200 ; 363: 418-423
3. Pielak RM, Schnell JR, Chou JJ. Mechanism of drug inhibition and drug resistance of influenza A M2 channel. Proc Natl Acad Sci U S A. 2009 ; 106: 7379-7384
4. Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A(H1N1) under an emergency IND program in the United States. Clin Infect Dis. 2011 ; 52: 695-706
5. Sorbello A, Jones SC, Carter W, Struble K. Safety of peramivir assessed under the FDA emergency use authorization (EUA) to treat hospitalized patients infected with 2009 H1N1 influenza virus. Oral presentation at: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ; Boston, MA ;..
6. Centers for Disease Control and Prevention. Emergency use authorization of peramivir IV fact sheet for health care providers. 2009. http://www.cdc.gov/ h1n1flu/eua/pdf/final-hcp-fact-sheet-peramivirIV-CDC.pdf.
7. Young D, Fowler C, Bush K. RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza. Philos Trans R Soc London. 2001 ; 356: 1905-1913
8. Swan S, Marbury T, Smith W, et al. Safety and pharmacokinetics of peramivir following intravenous administration in subjects with renal impairment. Poster presented at: 47th Annual Meeting of the Infectious Diseases Society of America ; Philadelphia, PA ;..
9. He G, Massarella J, Ward P. Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet. 1999 ; 37: 471-484
10. Beigel J, Harman LA, Collis PJ, et al. Pharmacokinetic and safety evaluations of escalating doses of peramivir administered intravenously in healthy volunteers. Poster presented at: 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ; Chicago, IL ;..
11. St Louis, MO: Forest Pharmaceuticals ; 2006:
12. Bantia S, Upshaw R, Babu YS Antiviral Res. In Press ;
13. Bantia S, Kellogg D, Parker CD, Babu YS. Combination of peramivir and rimantadine demonstrate synergistic antiviral effects in sub-lethal influenza A (H3N2) virus mouse model. Antiviral Res. 2010 ; 88: 276-280
14. Smee DF, Hurst BL, Wong M-H, et al. Combinations of oseltamivir and peramivir for the treatment of influenza a (H1N1) virus infections in cell culture and in mice. Antiviral Res. 2010 ; 88: 38-44
15. Govorkova EA, Fan H-B, Tan M, Webster RG. Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother. 2004 ; 48: 4855-4863
16. Guidance for Industry: In Vivo Drug Metabolism/Drug Interaction Studies-Study Design, Data Analysis, and Recommendations for Dosing and Labeling. Rockville, MD: Food and Drug Administration ; 1999:
17. Satin L, Haugen G, Waugh A, Collis P, Hernandez J, Hollister A. Intravenous (IV) peramivir was not associated with repolarization abnormalities in a thorough QT/QTc electrocardiographic (ECG) study. Poster presented at: 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ; Boston, MA ;..
18. Kohno S, Yen MY, Cheong HJ, et al. Single-intravenous peramivir vs oral oseltamivir to treat acute, uncomplicated influenza in the outpatient setting: a phase III randomized, double-blind trial. Oral presentation at: 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ; San Francisco, CA ;..
19. Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B infection in high-risk patients. Int J Infect Dis. 2010 ; 14 (suppl 1). e85 - e86
20. Ison MG, McGeer AJ, Hui DS, et al. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza. Oral presentation at: XI International Symposium on Respiratory Viral Infections ; Bangkok, Thailand ;..
21. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One. 2010 ; 4 ( 2 ):
22. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010 ; 7 ( 11 ):
23. Bantia S, Parker CD, Ananth SL, et al. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother. 2001 ; 45: 1162-1167
24. Kohno S, Kida H, Mizuguchi M, Shimada J. Efficacy and safety of intravenous peramivir for the treatment of seasonal influenza. Antimicrob Agents Chemother. 2010 ; 54: 4568-4574
25. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med. 2009 ; 360: 953-956
26. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG. Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol. 2009 ; 83: 10366-10373